The global market for synthetic data generation is rapidly growing as organizations in various industries seek cost-effective and privacy-compliant alternatives to real data for training machine learning models and conducting data-driven research. The market is estimated to reach $REDACTED billion by 2028, with North America leading in adoption due to the presence of leading global companies and advanced technologies like AI and ML.
Artificial intelligence (AI) has the potential to deliver significant productivity gains, but its current adoption may further consolidate the dominance of Big Tech companies, raising concerns among antitrust authorities.
The use of artificial intelligence (AI) by American public companies is on the rise, with over 1,000 companies mentioning the technology in their quarterly reports this summer; however, while there is a lot of hype surrounding AI, there are also signs that the boom may be slowing, with the number of people using generative AI tools beginning to fall, and venture capitalists warning entrepreneurs about the complexities and expenses involved in building a profitable AI start-up.
AI-assisted drug discovery has led to the discovery of a new antibiotic called halicin, which has the potential to kill antibiotic-resistant bacteria, marking a significant breakthrough in addressing the public health issue of superbugs; the use of AI has expedited the drug discovery process by analyzing vast amounts of medical data and predicting the properties of molecules.
The global artificial intelligence in genomics market is projected to reach USD 12.5 billion by 2032, with a CAGR of 39.2% during the period 2023-2032, driven by the increasing adoption of AI in genomics research for analysis and personalized medicine.
More than 25% of investments in American startups this year have gone to AI-related companies, which is more than double the investment levels from the previous year. Despite a general downturn in startup funding across various industries, AI companies are resilient and continue to attract funding, potentially due to the widespread applicability of AI technologies across different sectors. The trend suggests that being an AI company may become an expected part of a startup's business model.
Artificial intelligence (AI) has the potential to greatly improve health care globally by expanding access to health services, according to Google's chief health officer, Karen DeSalvo. Through initiatives such as using AI to monitor search queries for potential self-harm, as well as developing low-cost ultrasound devices and automated screening for tuberculosis, AI can address health-care access gaps and improve patient outcomes.
Artificial intelligence (AI) techniques, particularly machine learning, are increasingly being used in drug research and development (R&D), with applications expanding beyond small molecules to include large-molecule modalities such as antibodies, gene therapies, and RNA-based therapies. These therapies, which make up a significant portion of the biopharma industry's current and future commercial potential, are expected to represent approximately 50% of the oncology market by revenue in 2030, with the majority coming from antibodies.
Artificial intelligence (AI) is being explored as a potential solution to end the opioid epidemic, with innovations ranging from identifying at-risk individuals to detecting drug contamination and reducing overdoses, but concerns about discrimination and misinformation must be addressed.
The rise of artificial intelligence (AI) is a hot trend in 2023, with the potential to add trillions to the global economy by 2030, and billionaire investors are buying into AI stocks like Nvidia, Meta Platforms, Okta, and Microsoft.
An AI-generated COVID drug enters clinical trials, GM and Google strengthen their AI partnership, and Israel unveils an advanced AI-powered surveillance plane, among other AI technology advancements.
The global AI market is projected to reach $2 trillion by 2030, with companies like Amazon and Meta Platforms making significant investments in AI to drive growth and diversify their offerings.
The global neuroscience antibodies and assays market is projected to grow by USD 1.83 billion from 2022 to 2027, with North America contributing significantly to the market's growth due to the rising need for diagnosing neurological disorders.
The pharmaceutical market is expected to grow significantly by 2030, reaching $3,206 billion, driven by advances in healthcare technologies, increasing healthcare expenditures, and the rise of chronic diseases. The Business Research Company offers comprehensive reports to assist pharmaceutical companies with informed decision-making and staying competitive in this dynamic sector.
AI is revolutionizing scientific research by accelerating drug discovery, predicting protein structures, improving weather forecasting, controlling nuclear fusion, automating laboratory work, and enhancing data analysis, allowing scientists to explore new frontiers and increase research productivity.
The finance industry leads the way in AI adoption, with 48% of professionals reporting revenue increases and 43% reporting cost reductions as a result, while IT, professional services, and finance and insurance are the sectors with the highest demand for AI talent.
Artificial Intelligence (AI) has the potential to improve healthcare, but the U.S. health sector struggles with implementing innovations like AI; to build trust and accelerate adoption, innovators must change the purpose narrative, carefully implement AI applications, and assure patients and the public that their needs and rights will be protected.
The artificial intelligence (AI) market is rapidly growing, with an expected compound annual growth rate (CAGR) of 37.3% and a projected valuation of $1.81 trillion by the end of the decade, driven by trends such as generative AI and natural language processing (NLP). AI assistants are being utilized to automate and digitize service sectors like legal services and public administration, while Fortune 500 companies are adopting AI to enhance their strategies and operations. The rise of generative AI and the growth of NLP systems are also prominent trends, and AI's use in healthcare is expected to increase significantly in areas such as diagnostics, treatment, and drug discovery.
The use of generative AI, combined with federated and active learning, can accelerate the development of protein drugs by improving predictions of drug properties and enabling collaboration among biopharmaceutical companies while protecting their competitive interests.